Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16

Merck (NYSE: MRK) announced that its investigational monoclonal antibody, tulisokibart, met the primary endpoint in a Phase 2b trial for treating moderate to severe hidradenitis suppurativa (HS). At week 16, 72% of patients in the high-dose group and 64% in the medium-dose group achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50), significantly outperforming the 35% response in the placebo group. The study also indicated improvements in patient quality of life, with notable reductions in the Dermatology Life Quality Index (DLQI) for the high- and medium-dose cohorts compared to placebo.